Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ling-Hua Meng

Showing results (1-10 of 63) with videos related to

Pageof 7
Sort By:
Acta Pharmacologica Sinica|December 4, 2019
CRISPR-cas9: a powerful tool towards precision medicine in cancer treatmentHui Xing, Ling-Hua Meng
Acta Pharmacologica Sinica|August 29, 2007
Salvicine, a novel topoisomerase II inhibitor, exerts its potent anticancer activity by ROS generationLing-hua Meng, Jian Ding
Acta Pharmacologica Sinica|September 17, 2020
Emerging roles of class I PI3K inhibitors in modulating tumor microenvironment and immunityPu Sun, Ling-Hua Meng
Acta Pharmacologica Sinica|November 23, 2021
The double faced role of xanthine oxidoreductase in cancerMan-Man Chen, Ling-Hua Meng
Acta Pharmacologica Sinica|August 25, 2015
Toward rapamycin analog (rapalog)-based precision cancer therapyLing-hua Meng, X F Steven Zheng
Acta Pharmacologica Sinica|September 15, 2015
PI3K isoform-selective inhibitors: next-generation targeted cancer therapiesXiang Wang, Jian Ding, Ling-hua Meng
Biochimie|December 13, 2006
Mitochondrial topoisomerases and alternative splicing of the human TOP1mt geneHongliang Zhang, Ling-Hua Meng, Yves Pommier
Current Topics in Medicinal Chemistry|February 7, 2003
Non-camptothecin DNA topoisomerase I inhibitors in cancer therapyLing-Hua Meng, Zhi-Yong Liao, Yves Pommier
Expert Opinion on Investigational Drugs|February 10, 2010
New microtubule-inhibiting anticancer agentsSi-Meng Chen, Ling-Hua Meng, Jian Ding
Acta Pharmacologica Sinica|April 6, 2018
Oncogene-induced senescence: a double edged sword in cancerXue-Ling Liu, Jian Ding, Ling-Hua Meng
Pageof 7

Showing results (1-10 of 63) with videos related to

Sort By:
Pageof 7
Acta Pharmacologica Sinica|December 4, 2019
CRISPR-cas9: a powerful tool towards precision medicine in cancer treatmentHui Xing, Ling-Hua Meng
Acta Pharmacologica Sinica|August 29, 2007
Salvicine, a novel topoisomerase II inhibitor, exerts its potent anticancer activity by ROS generationLing-hua Meng, Jian Ding
Acta Pharmacologica Sinica|September 17, 2020
Emerging roles of class I PI3K inhibitors in modulating tumor microenvironment and immunityPu Sun, Ling-Hua Meng
Acta Pharmacologica Sinica|November 23, 2021
The double faced role of xanthine oxidoreductase in cancerMan-Man Chen, Ling-Hua Meng
Acta Pharmacologica Sinica|August 25, 2015
Toward rapamycin analog (rapalog)-based precision cancer therapyLing-hua Meng, X F Steven Zheng
Acta Pharmacologica Sinica|September 15, 2015
PI3K isoform-selective inhibitors: next-generation targeted cancer therapiesXiang Wang, Jian Ding, Ling-hua Meng
Biochimie|December 13, 2006
Mitochondrial topoisomerases and alternative splicing of the human TOP1mt geneHongliang Zhang, Ling-Hua Meng, Yves Pommier
Current Topics in Medicinal Chemistry|February 7, 2003
Non-camptothecin DNA topoisomerase I inhibitors in cancer therapyLing-Hua Meng, Zhi-Yong Liao, Yves Pommier
Expert Opinion on Investigational Drugs|February 10, 2010
New microtubule-inhibiting anticancer agentsSi-Meng Chen, Ling-Hua Meng, Jian Ding
Acta Pharmacologica Sinica|April 6, 2018
Oncogene-induced senescence: a double edged sword in cancerXue-Ling Liu, Jian Ding, Ling-Hua Meng
Pageof 7